TissueGene licensee Kolon Life Science (KSDQ:102940) of Korea said this week that it inked a deal with Japan’s Mitsubishi Tanabe Pharma Corp. (TYO:4508) to develop and commercialize Kolon’s Invossa, the 1st cell-mediated gene therapy injection for degenerative osteoarthritis for the Japanese market.
The deal represents the largest single-territory deal on record for Korea, according to Kolon Life Science. According to the agreement, Mitsubishi Tanabe will pay $24 million up front, plus additional payments of up to $410 million pending development, regulatory and commercial milestones, as well as a double-digit sales royalty.
Get the full story at our sister site, Drug Delivery Business News.
The post TissueGene subsidiary inks development deal for osteoarthritis injection appeared first on MassDevice.
from MassDevice http://ift.tt/2f5bv62
Cap comentari:
Publica un comentari a l'entrada